Yibai Pharmaceutical announced that it is expected to achieve net profit of -88.8 million yuan to -74 million yuan in the semi-annual period of 2026, which will result in a loss. The company expects to achieve net profit of -97.2 million yuan to -81 million yuan after deducting non-recurring profit and loss attributable to the owner of the parent company for the first half year of 2026. During the reporting period, sales of the company's main products declined, leading to a 30% drop in the company's revenue; although the company's costs and expenses are expected to drop by 26%, the amount of costs and expenses is still greater than the amount of revenue, resulting in losses in the current period.

Yibai Pharmaceutical announced that it is expected to achieve net profit of -88.8 million yuan to -74 million yuan in the semi-annual period of 2026, which will result in a loss. The company expects to achieve net profit of -97.2 million yuan to -81 million yuan after deducting non-recurring profit and loss attributable to the owner of the parent company for the first half year of 2026. During the reporting period, sales of the company's main products declined, leading to a 30% drop in the company's revenue; although the company's costs and expenses are expected to drop by 26%, the amount of costs and expenses is still greater than the amount of revenue, resulting in losses in the current period.